Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT00709787
Collaborator
(none)
899
2
8
449.5
55.8
Study Details
Study Description
Brief Summary
To assess the pattern of hypertension in the population in terms of presence of additional risk factors (ARF) and cardiovascular risk stratification.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
routine physician visits
Study Design
Study Type:
Observational
Actual Enrollment
:
899 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management
Study Start Date
:
Jun 1, 2008
Actual Primary Completion Date
:
Feb 1, 2009
Actual Study Completion Date
:
Feb 1, 2009
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Hypertensive Subjects undergoing primary prevention
|
Other: Usual Care
Normal care for hypertensive patients with risk factors for CHD
|
Outcome Measures
Primary Outcome Measures
- Description of hypertensive patients in terms of presence of associated cardiovascular (CV) risk factors (number of additional CV risk factors and frequency) []
Secondary Outcome Measures
- Description of pattern of management of HT and CVD prevention, through lifestyle and use of drug therapies, []
- Estimate adherence to treatment using the Morisky Adherence Scale (MAS) []
- Estimation of hypertensive patients CV risk stratification based on ESH/ESC Hypertension Guidelines 2007 and to compare it with physicians' estimation of CV risk. []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Age 18 to 80 years old
-
Patients with hypertension: newly diagnosed and /or already diagnosed and treated , whether at goal or not for the blood pressure level;
-
Patients with no history of CHD/CVD
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Pfizer Investigational Site | Varazdin | Croatia | 42000 | |
| 2 | Pfizer Investigational Site | Prague 4 | Czechia | 140 00 |
Sponsors and Collaborators
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
ClinicalTrials.gov Identifier:
NCT00709787
Other Study ID Numbers:
- A3841059
First Posted:
Jul 3, 2008
Last Update Posted:
Jan 27, 2021
Last Verified:
Jan 1, 2021
Keywords provided by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Additional relevant MeSH terms: